62 - Scientific Plenary
Ascites predicts degree of treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, Fallopian tube, and peritoneal cancers
Sunday, March 23, 2014: 11:59 AM
Ballroom B/C (Tampa Convention Center)
J. S. Ferriss1, J. Java2, R. A. Burger3, M. A. Bookman4, G. Fleming5, B. J. Monk6, J. L. Walker7, H. D. Homesley8, J. M. Fowler9, B. E. Greer10 and M. P. Boente11
1Temple University School of Medicine, Philadelphia, PA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3University of Pennsylvania, Philadelphia, PA, 4University of Arizona Cancer Center, Tucson, AZ, 5University of Chicago Medical Center, Chicago, IL, 6University of Arizona Cancer Center, Phoenix, AZ, 7The University of Oklahoma, Oklahoma City, OK, 8East Carolina University, Greensville, NC, 9The Ohio State University, Columbus, OH, 10University of Washington Medical Center, Seattle, WA, 11Minnesota Oncology Hematology PA, US Oncology, Edina, MN
